Banks - Regional
Compare Stocks
3 / 10Stock Comparison
CARE vs NBTB vs UVSP
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Banks - Regional
CARE vs NBTB vs UVSP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Banks - Regional | Banks - Regional | Banks - Regional |
| Market Cap | $580M | $2.36B | $1.10B |
| Revenue (TTM) | $255M | $867M | $518M |
| Net Income (TTM) | $31M | $169M | $91M |
| Gross Margin | 61.7% | 72.1% | 61.0% |
| Operating Margin | 15.7% | 25.3% | 21.9% |
| Forward P/E | 4.8x | 10.8x | 11.1x |
| Total Debt | $179M | $327M | $352M |
| Cash & Equiv. | $105M | $185M | $554M |
CARE vs NBTB vs UVSP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Carter Bankshares, … (CARE) | 100 | 370.7 | +270.7% |
| NBT Bancorp Inc. (NBTB) | 100 | 144.3 | +44.3% |
| Univest Financial C… (UVSP) | 100 | 235.8 | +135.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CARE vs NBTB vs UVSP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CARE is the clearest fit if your priority is growth exposure.
- Rev growth 6.2%, EPS growth 32.1%
- Beta 0.56 vs UVSP's 1.01
- +68.4% vs NBTB's +9.3%
NBTB is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 12 yrs, beta 0.89, yield 3.2%
- Lower volatility, beta 0.89, Low D/E 17.3%, current ratio 1.60x
- Beta 0.89, yield 3.2%, current ratio 1.60x
UVSP has the current edge in this matchup, primarily because of its strength in long-term compounding and valuation efficiency.
- 141.5% 10Y total return vs CARE's 111.1%
- PEG 0.76 vs NBTB's 1.54
- PEG 0.76 vs 1.54
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.4% NII/revenue growth vs UVSP's 3.6% | |
| Value | PEG 0.76 vs 1.54 | |
| Quality / Margins | Efficiency ratio 0.4% vs NBTB's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.56 vs UVSP's 1.01 | |
| Dividends | 3.2% yield, 12-year raise streak, vs UVSP's 2.3%, (1 stock pays no dividend) | |
| Momentum (1Y) | +68.4% vs NBTB's +9.3% | |
| Efficiency (ROA) | Efficiency ratio 0.4% vs NBTB's 0.5% |
CARE vs NBTB vs UVSP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CARE vs NBTB vs UVSP — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NBTB leads in 2 of 6 categories
UVSP leads 2 • CARE leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NBTB leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NBTB is the larger business by revenue, generating $867M annually — 3.4x CARE's $255M. NBTB is the more profitable business, keeping 19.5% of every revenue dollar as net income compared to CARE's 12.3%.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $255M | $867M | $518M |
| EBITDAEarnings before interest/tax | $46M | $241M | $119M |
| Net IncomeAfter-tax profit | $31M | $169M | $91M |
| Free Cash FlowCash after capex | $30M | $225M | $92M |
| Gross MarginGross profit ÷ Revenue | +61.7% | +72.1% | +61.0% |
| Operating MarginEBIT ÷ Revenue | +15.7% | +25.3% | +21.9% |
| Net MarginNet income ÷ Revenue | +12.3% | +19.5% | +17.5% |
| FCF MarginFCF ÷ Revenue | +12.5% | +25.2% | +18.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +8.3% | +39.5% | +23.1% |
Valuation Metrics
UVSP leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, UVSP trades at a 34% valuation discount to CARE's 18.7x P/E. Adjusting for growth (PEG ratio), UVSP offers better value at 0.84x vs NBTB's 1.93x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $580M | $2.4B | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $653M | $2.5B | $902M |
| Trailing P/EPrice ÷ TTM EPS | 18.69x | 13.57x | 12.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 4.76x | 10.83x | 11.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.93x | 0.84x |
| EV / EBITDAEnterprise value multiple | 16.33x | 10.38x | 7.53x |
| Price / SalesMarket cap ÷ Revenue | 2.28x | 2.72x | 2.13x |
| Price / BookPrice ÷ Book value/share | 1.40x | 1.21x | 1.18x |
| Price / FCFMarket cap ÷ FCF | 18.23x | 10.78x | 11.39x |
Profitability & Efficiency
UVSP leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UVSP delivers a 9.8% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $8 for CARE. NBTB carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to CARE's 0.43x. On the Piotroski fundamental quality scale (0–9), CARE scores 8/9 vs UVSP's 7/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | +7.6% | +9.5% | +9.8% |
| ROA (TTM)Return on assets | +0.7% | +1.1% | +1.1% |
| ROICReturn on invested capital | +5.7% | +7.9% | +6.5% |
| ROCEReturn on capital employed | +1.5% | +2.4% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.43x | 0.17x | 0.37x |
| Net DebtTotal debt minus cash | $73M | $142M | -$202M |
| Cash & Equiv.Liquid assets | $105M | $185M | $554M |
| Total DebtShort + long-term debt | $179M | $327M | $352M |
| Interest CoverageEBIT ÷ Interest expense | 0.39x | 1.05x | 0.60x |
Total Returns (Dividends Reinvested)
Evenly matched — CARE and UVSP each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $18,800 today (with dividends reinvested), compared to $12,950 for NBTB. Over the past 12 months, CARE leads with a +68.4% total return vs NBTB's +9.3%. The 3-year compound annual growth rate (CAGR) favors UVSP at 33.5% vs NBTB's 15.6% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +34.7% | +9.6% | +21.5% |
| 1-Year ReturnPast 12 months | +68.4% | +9.3% | +32.7% |
| 3-Year ReturnCumulative with dividends | +94.6% | +54.5% | +138.1% |
| 5-Year ReturnCumulative with dividends | +88.0% | +29.5% | +47.6% |
| 10-Year ReturnCumulative with dividends | +111.1% | +102.2% | +141.5% |
| CAGR (3Y)Annualised 3-year return | +24.8% | +15.6% | +33.5% |
Risk & Volatility
Evenly matched — CARE and UVSP each lead in 1 of 2 comparable metrics.
Risk & Volatility
CARE is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than UVSP's 1.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. UVSP currently trades 99.4% from its 52-week high vs NBTB's 96.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.56x | 0.89x | 1.01x |
| 52-Week HighHighest price in past year | $26.41 | $46.92 | $39.00 |
| 52-Week LowLowest price in past year | $15.37 | $39.20 | $27.91 |
| % of 52W HighCurrent price vs 52-week peak | +99.1% | +96.3% | +99.4% |
| RSI (14)Momentum oscillator 0–100 | 75.2 | 54.2 | 68.5 |
| Avg Volume (50D)Average daily shares traded | 273K | 234K | 178K |
Analyst Outlook
NBTB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CARE as "Buy", NBTB as "Hold", UVSP as "Hold". Consensus price targets imply 3.2% upside for CARE (target: $27) vs -12.3% for UVSP (target: $34). For income investors, NBTB offers the higher dividend yield at 3.16% vs UVSP's 2.27%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $27.00 | $46.00 | $34.00 |
| # AnalystsCovering analysts | 4 | 10 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | +3.2% | +2.3% |
| Dividend StreakConsecutive years of raises | 0 | 12 | 1 |
| Dividend / ShareAnnual DPS | — | $1.43 | $0.88 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.4% | +0.4% | +3.1% |
NBTB leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). UVSP leads in 2 (Valuation Metrics, Profitability & Efficiency). 2 tied.
CARE vs NBTB vs UVSP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CARE or NBTB or UVSP a better buy right now?
For growth investors, NBT Bancorp Inc.
(NBTB) is the stronger pick with 10. 4% revenue growth year-over-year, versus 3. 6% for Univest Financial Corporation (UVSP). Univest Financial Corporation (UVSP) offers the better valuation at 12. 3x trailing P/E (11. 1x forward), making it the more compelling value choice. Analysts rate Carter Bankshares, Inc. (CARE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CARE or NBTB or UVSP?
On trailing P/E, Univest Financial Corporation (UVSP) is the cheapest at 12.
3x versus Carter Bankshares, Inc. at 18. 7x. On forward P/E, Carter Bankshares, Inc. is actually cheaper at 4. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Univest Financial Corporation wins at 0. 76x versus NBT Bancorp Inc. 's 1. 54x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CARE or NBTB or UVSP?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +88. 0%, compared to +29. 5% for NBT Bancorp Inc. (NBTB). Over 10 years, the gap is even starker: UVSP returned +141. 5% versus NBTB's +102. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CARE or NBTB or UVSP?
By beta (market sensitivity over 5 years), Carter Bankshares, Inc.
(CARE) is the lower-risk stock at 0. 56β versus Univest Financial Corporation's 1. 01β — meaning UVSP is approximately 80% more volatile than CARE relative to the S&P 500. On balance sheet safety, NBT Bancorp Inc. (NBTB) carries a lower debt/equity ratio of 17% versus 43% for Carter Bankshares, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CARE or NBTB or UVSP?
By revenue growth (latest reported year), NBT Bancorp Inc.
(NBTB) is pulling ahead at 10. 4% versus 3. 6% for Univest Financial Corporation (UVSP). On earnings-per-share growth, the picture is similar: Carter Bankshares, Inc. grew EPS 32. 1% year-over-year, compared to 12. 5% for NBT Bancorp Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CARE or NBTB or UVSP?
NBT Bancorp Inc.
(NBTB) is the more profitable company, earning 19. 5% net margin versus 12. 3% for Carter Bankshares, Inc. — meaning it keeps 19. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBTB leads at 25. 3% versus 15. 7% for CARE. At the gross margin level — before operating expenses — NBTB leads at 72. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CARE or NBTB or UVSP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Univest Financial Corporation (UVSP) is the more undervalued stock at a PEG of 0. 76x versus NBT Bancorp Inc. 's 1. 54x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Carter Bankshares, Inc. (CARE) trades at 4. 8x forward P/E versus 11. 1x for Univest Financial Corporation — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CARE: 3. 2% to $27. 00.
08Which pays a better dividend — CARE or NBTB or UVSP?
In this comparison, NBTB (3.
2% yield), UVSP (2. 3% yield) pay a dividend. CARE does not pay a meaningful dividend and should not be held primarily for income.
09Is CARE or NBTB or UVSP better for a retirement portfolio?
For long-horizon retirement investors, NBT Bancorp Inc.
(NBTB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89), 3. 2% yield, +102. 2% 10Y return). Both have compounded well over 10 years (NBTB: +102. 2%, CARE: +111. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CARE and NBTB and UVSP?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CARE is a small-cap quality compounder stock; NBTB is a small-cap deep-value stock; UVSP is a small-cap deep-value stock. NBTB, UVSP pay a dividend while CARE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.